Home Diabetes and Endocrinology Cushing’s Sx Described in Infant Treated With Ophthalmic Steroid

Cushing’s Sx Described in Infant Treated With Ophthalmic Steroid

Four-month-old developed ICS after six weeks of intranasal dexamethasone ophthalmic solution

FRIDAY, April 8, 2016 (HealthDay News) — In a case report published online April 7 in Pediatrics, iatrogenic Cushing’s syndrome (ICS) is described in an infant following intranasal usage of dexamethasone ophthalmic solution.

Sarah Orton, M.D., and Marisa Censani, M.D., from Weill Cornell Medicine in New York City, present the case of a 4-month-old male infant who was born at 26 weeks of gestation. He was treated for nasal obstruction with intranasal dexamethasone ophthalmic solution administered for six weeks.

The researchers found that after steroid introduction, the infant’s growth velocity had decreased. He was noted to have large ruddy cheeks with moon facies on exam. A morning cortisol level of <0.4 µg/dL was obtained and the patient was diagnosed with ICS. Dexamethasone taper was initiated, with discontinuation by four months post-ophthalmic steroid initiation. His morning cortisol level was 1.6 µg/dL by one month post-steroid use and his Cushingoid facies had resolved by 2.5 months post-steroid use. At 4.5 months following discontinuation of steroids, the infant’s hypothalamic-pituitary-adrenal axis had recovered fully.

“Because of the small body surface area and supine position during administration, infants are particularly susceptible to ICS,” the authors write. “Close monitoring of these patients’ height and weight should occur while on steroid treatment, with every effort made to decrease or discontinue steroid use when possible.”

Full Text (subscription or payment may be required)

Copyright © 2016 HealthDay. All rights reserved.